FIL Limited Form 8.3 - Abbvie Inc (6739M)
12 Mayo 2020 - 8:31AM
UK Regulatory
TIDM0Y7T
RNS Number : 6739M
FIL Limited
12 May 2020
Ap19
FORM 8.3
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013
DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES
REPRESENTING 1% OR MORE
1. KEY INFORMATION
Name of person dealing FMR LLC and/or one or more
(Note 1) of its direct or indirect
subsidiaries
And
FIL Limited and/or one
or more of its direct and
indirect subsidiaries
Company dealt in ABBVIE INC
==========================
Class of relevant security ORDINARY SHARES
to which the dealings
being disclosed relate
(Note 2)
==========================
Date of dealing 11-May-2020
==========================
2. INTERESTS AND SHORT POSITIONS
(a) Interests and short positions (following dealing) in the
class of relevant
security dealt in (Note 3)
Long Short
Number (%) Number (%)
========== ====== =========== ======
(1) Relevant securities 33,509,651 2.26%
================== ===================
(2) Derivatives (other
than options)
================== ===================
(3) Options and agreements
to purchase/sell
================== ===================
Total 33,509,651 2.26%
================== ===================
THE ABOVE INCLUDES A TRANSFER IN OF 648,888 ORDINARY SHARES
(b) Interests and short positions in relevant securities of the
company, other than the class dealt
in (Note 3)
Class of relevant security: Long Short
Number (%) Number (%)
========= ====== =========== ======
(1) Relevant securities
=================== =====================
(2) Derivatives (other
than options)
=================== =====================
(3) Options and agreements
to purchase/sell
=================== =====================
Total
=================== =====================
Ap20
1. DEALINGS (Note 4)
(a) Purchases and sales
Purchase/Sale Number of relevant securities Price per unit (Note 5)
Purchase 900 84.49 USD/Share
------------------------------ ------------------------
Purchase 100 84.60 USD/Share
------------------------------ ------------------------
Purchase 800 84.72 USD/Share
------------------------------ ------------------------
Purchase 763 85.02 USD/Share
------------------------------ ------------------------
Purchase 75,017 85.06 USD/Share
------------------------------ ------------------------
Purchase 14,620 85.07 USD/Share
------------------------------ ------------------------
Sale 5,174 86.62 USD/Share
------------------------------ ------------------------
Sale 1,700 86.78 USD/Share
------------------------------ ------------------------
Sale 1,300 86.80 USD/Share
------------------------------ ------------------------
Sale 1,824 86.89 USD/Share
------------------------------ ------------------------
Sale 1,100 87.01 USD/Share
------------------------------ ------------------------
Sale 2,682 87.09 USD/Share
------------------------------ ------------------------
Sale 18,220 87.13 USD/Share
------------------------------ ------------------------
Purchase 600 87.70 USD/Share
------------------------------ ------------------------
Purchase 10,456 87.88 USD/Share
------------------------------ ------------------------
Purchase 6,959 87.90 USD/Share
------------------------------ ------------------------
Purchase 39,137 88.00 USD/Share
------------------------------ ------------------------
Purchase 17,285 88.14 USD/Share
------------------------------ ------------------------
Purchase 117,656 88.15 USD/Share
------------------------------ ------------------------
Purchase 48,366 88.20 USD/Share
------------------------------ ------------------------
Sale 7,942 86.61 USD/Share
------------------------------ ------------------------
Purchase 2 83.96 USD/Share
------------------------------ ------------------------
Purchase 2,871 86.33 USD/Share
------------------------------ ------------------------
Sale 56 86.35 USD/Share
------------------------------ ------------------------
Purchase 6 86.44 USD/Share
------------------------------ ------------------------
Sale 1 84.21 USD/Share
------------------------------ ------------------------
Sale 1 84.24 USD/Share
------------------------------ ------------------------
Sale 1 84.27 USD/Share
------------------------------ ------------------------
Sale 1 84.29 USD/Share
------------------------------ ------------------------
Sale 1 84.31 USD/Share
------------------------------ ------------------------
Sale 1 84.32 USD/Share
------------------------------ ------------------------
Sale 1 84.35 USD/Share
------------------------------ ------------------------
Sale 1 84.54 USD/Share
------------------------------ ------------------------
Sale 1 84.56 USD/Share
------------------------------ ------------------------
Sale 1 84.62 USD/Share
------------------------------ ------------------------
Sale 1 84.63 USD/Share
------------------------------ ------------------------
Sale 1 84.67 USD/Share
------------------------------ ------------------------
Sale 1 84.72 USD/Share
------------------------------ ------------------------
Sale 1 84.74 USD/Share
------------------------------ ------------------------
Sale 2 84.77 USD/Share
------------------------------ ------------------------
Sale 1 84.79 USD/Share
------------------------------ ------------------------
Sale 1 84.81 USD/Share
------------------------------ ------------------------
Sale 1 84.88 USD/Share
------------------------------ ------------------------
(b) Derivatives transactions (other than options transactions)
Product Nature of transaction Number of relevant Price per
name, (Note 6) securities unit
e.g. CFD (Note 7) (Note 5)
(c) Options transactions in respect of existing relevant securities
(i) Writing, selling, purchasing or varying
Product Writing, Number of Exercise Type, Expiry Option
name, selling, securities price e.g. American, date money paid/received
e.g. call purchasing, to which European per unit
option varying the option etc. (Note 5)
etc. relates (Note
7)
(ii) Exercising
Product name, Number of securities Exercise price
e.g. call option per unit (Note
5)
(d) Other dealings (including transactions in respect of new
securities) (Note 4)
Nature of transaction Details Price per unit
(Note 8) (if applicable)
(Note 5)
Ap21
2. OTHER INFORMATION
Agreements, arrangements or understandings relating to options
or derivatives
Full details of any agreement, arrangement or understanding
between the person disclosing and any other person relating to the
voting rights of any relevant securities under any option referred
to on this form or
relating to the voting rights or future acquisition or disposal of any
relevant securities to which any derivative referred to on this
form is referenced.
If none, this should be stated.
Is a Supplemental Form 8 attached? (Note 9) NO
Date of disclosure 12-May-2020
Contact name Paul Clark
================
Telephone number 00353 1 223 1447
================
If a connected EFM, name
of offeree/offeror with
which connected
================
If a connected EFM, state
nature of connection (Note
10)
================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
ISEKKBBBNBKDCPD
(END) Dow Jones Newswires
May 12, 2020 09:31 ET (13:31 GMT)
Allergan (LSE:0Y7T)
Gráfica de Acción Histórica
De Dic 2024 a Ene 2025
Allergan (LSE:0Y7T)
Gráfica de Acción Histórica
De Ene 2024 a Ene 2025
